Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?
Document Type
Journal Article
Publication Date
3-1-2021
Journal
Journal of Acquired Immune Deficiency Syndromes
Volume
86
Issue
3
Inclusive Pages
e80-e82
DOI
10.1097/QAI.0000000000002557
APA Citation
Levy, M. E., Agopian, A., Magnus, M., Rawls, A., Opoku, J., Kharfen, M., Greenberg, A. E., & Kuo, I. (2021). Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?. Journal of Acquired Immune Deficiency Syndromes, 86 (3). http://dx.doi.org/10.1097/QAI.0000000000002557
Peer Reviewed
1
